From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
AHFS/ International Drug Names
Routes of
ATC code
CAS Number
PubChem CID
ECHA InfoCard 100.118.935
Chemical and physical data
Formula C22H29N3O4S
Molar mass 431.54 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Lafutidine (INN) is a second generation histamine H2 receptor antagonist having multimodal mechanism of action and used to treat gastrointestinal disorders. It is marketed in Japan and India.

Medical use[edit]

Lafutidine is used to treat gastric ulcers, duodenal ulcers, as well as wounds in the lining of the stomach associated with acute gastritis and acute exacerbation of chronic gastritis.[1][2]

Adverse effects[edit]

Adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea, vomiting and dizziness.[2]

Mechanism of action[edit]

Like other H2 receptor antagonists it prevents the secretion of gastric acid.[2] It also activates calcitonin gene-related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of Helicobacter pylori to gastric cells.[2]

Trade names[edit]

It is marketed in Japan as Stogar by UCB[1] and in India as Lafaxid by Zuventus Healthcare.[2]


  1. ^ a b UCB Japan Revised: April 2005 Stogar tablets
  2. ^ a b c d e Zuventus Healthcare Ltd. India Lafaxid tablets